Clinical Trial Update: Irinotecan Liposomes for the Treatment of Neuroendocrine Carcinoma [Phase 4]

View source ↗

Summary

Phase 4 trial evaluating liposomal irinotecan for neuroendocrine tumors. The study is currently not yet recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Neuroendocrine Carcinoma
• Neuroendocrine Tumor

Drugs mentioned

• Liposomal irinotecan (liposomal irinotecan)

Snippet

Sponsor: First Affiliated Hospital Xi'an Jiaotong University | Conditions: Neuroendocrine Tumors | Phase 4 | Status: NOT_YET_RECRUITING